Clinical Trials Browser

Phase 1/2 × Stomach Neoplasms × irinotecan sucrosofate × Clear all

NCT03368963 2025-01-07

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Phase 1/2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms